Your browser doesn't support javascript.
loading
Urological complications after COVID 19 vaccine according to age, sex and manufacturer.
Shim, Sung Ryul; Kim, Kwang Taek; Park, Eunju; Pyun, Jong Hyun; Kim, Jae Heon; Chung, Benjamin I.
Afiliación
  • Shim SR; Department of Biomedical Informatics, College of Medicine, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365, Republic of Korea.
  • Kim KT; Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea.
  • Park E; Department of Urology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  • Pyun JH; Evidence Based Research Center, Kyungnam University, Changwon, Republic of Korea.
  • Kim JH; Department of Food and Nutrition, Kyungnam University College of Health Sciences, Changwon, Republic of Korea.
  • Chung BI; Department of Urology, Kangbuk Samsung Hospital, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Korea. docpjh79@hanmail.net.
World J Urol ; 41(8): 2255-2263, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37400660
OBJECTIVES: To examine the effects of age, sex, and type of COVID-19 vaccine on urological complications after vaccination with COVID-19. MATERIALS AND METHODS: We used the Vaccine Adverse Event Reporting System (VAERS) data from December 2020 to August 2022 to analyze urological symptoms post-vaccination adverse events (AEs) associated with COVID-19 vaccines authorized for the U.S. POPULATION: We collected AEs after 1-2 dose vaccination in VAERS, but not those after an additional booster shot. Age was divided into three groups (< 18 years, 18-64 years, and > 64 years), and compared incidence of AEs after vaccination with either mRNA vaccine (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) or a viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) as reported in VAERS data. RESULTS: Cumulative incidence rates (CIRs) of LUTS, voiding symptom, storage symptom, infection, and hematuria were 0.057, 0.282, 0.223, 1.245, and 0.214, respectively. By gender, CIRs OF LUTS, storage symptom, and infection were statistically significantly higher in women, whereas CIRs of voiding symptom and hematuria were statistically significantly higher in men. CIRs of AEs per 100,000 in age groups of < 18 years, 18-64 years, and > 64 years were 0.353, 1.403, and 4.067, respectively. All AE types except for voiding symptom displayed the highest CIRs in the Moderna vaccine group. CONCLUSIONS: Based on an updated analysis of available data, the prevalence of urologic complications following administration of COVID-19 vaccines is low. However, specific urologic complications such as gross hematuria are not low in incidence.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Female / Humans / Male Idioma: En Revista: World J Urol Año: 2023 Tipo del documento: Article Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Female / Humans / Male Idioma: En Revista: World J Urol Año: 2023 Tipo del documento: Article Pais de publicación: Alemania